INVESTORS
Potential Investors
To explore potential investment possibilities and request a nondisclosure agreement, please contact Business Development at info@recropharma.com
January 2010:
DEX-TD Phase I Clinical
Study initiated.
December 2009:
William Ashton joins Board
of Directors.
September 2009:
DEX-SL Phase I Clinical Study initiated in the U.S.
